Stephen A. Strickland

Jan 10, 2025 | onclive.com | Jorge Cortés |Stephen A. Strickland

OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how it is an exciting time for chronic myeloid leukemia (CML) treatment, with many options including 6 different drugs that have been very successful for patients, which give clinicians multiple options to tailor the therapy to their patients and consider whether CML could be curable. Video content above is prompted by the following:What are closing thoughts from you on what we’ve discussed today?

Jan 10, 2025 | onclive.com | Jorge Cortés |Stephen A. Strickland

OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options. Video content above is prompted by the following:Can you tell us about the trial design, key end points, and your impressions of the data?

Nov 7, 2023 | nature.com | Guillermo Garcia-Manero |Nikolai A. Podoltsev |Megan Othus |John Pagel |David A. Rizzieri |Guido Marcucci | +7 more

AbstractPrior experience indicated that use of higher doses of cytarabine during induction for acute myeloid leukemia (AML) with a histone deacetylase inhibitor resulted in high response rates. S1203 was a randomized multicenter trial for previously untreated patients aged 18–60 with AML which compared daunorubicin and cytarabine (DA), idarubicin with higher dose cytarabine (IA) and IA with vorinostat (IA + V). The primary endpoint was event free survival (EFS).

May 15, 2023 | ffnews.com | Lauren Towner |Dmitry Tokarev |Stephen A. Strickland

Copper.co, a leading provider of institutional digital asset custody and collateral management, today announced the appointment Jim Turley as a Non-Executive Director and the appointment of Dr Stephen Strickland as Chief Compliance Officer. Both appointments are effective immediately.

Jan 30, 2023 | newsbreak.com | Stephen A. Strickland

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.